2016 saw slump in FDA drug approvals, but 2017 could be return to form
FDA approvals could rebound in 2017 – but concerns about big pharma R&D productivity won’t go away.
FDA approvals could rebound in 2017 – but concerns about big pharma R&D productivity won’t go away.
Roche’s MS drug is among major drugs still to come in 2016.
In a record-breaking year for pharma, which drugs were the most outstanding?